MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM.

680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease.

WM-S1-030 is a highly potent, specific inhibitor of recepteur d'origine nantais (RON kinase, MST1R) with IC50 of 0.39 nM in in vitro enzyme activity.

Deuterated AZ5104 is a potent EGFR inhibitor.

PrDiAzK is a bifunctional amino acid. PrDiAzK can be site-selectively incorporated into proteins in both bacterial and mammalian cell culture. PrDiAzK can be used for proteome-wide incorporation via stochastic orthogonal recoding of translation (SORT).

BMVC-8C3O is a DNA G-quadruplexe (G4) ligand which can induce topological conversion of non-parallel to parallel forms in human telomeric DNA G4s.

(+)-Narwedine. Galantamine(Narwedin) is a competitive and reversible cholinesterase(AChE) inhibitor.

CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.

MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.

Utreloxastat is a compound used for the research of the disorders including α-synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1).

HDAC6 Degrader 13f (YZ268) is a selective HDAC6 degrader (PROTAC) with high potency, specific chemical probe to knock-down HDAC6.

Pseudouridine-5’-triphosphate (Pseudo-UTP) is one of the most commonly used modified nucleoside for the polymerase-mediated synthesis of RNA molecules. Compared with uridine-containing unmodified mRNAs, the application of pseudouridine-containing modified mRNAs exhibits better nuclease stability, immunogenicity, and translational properties.

pseudouridine-5’-triphosphate (Pseudo-UTP) is one of the most commonly used modified nucleoside for the polymerase-mediated synthesis of RNA molecules. Compared with uridine-containing unmodified mRNAs, the application of pseudouridine-containing modified mRNAs exhibits better nuclease stability, immunogenicity, and translational properties.

Pidobenzone is a dermatologic agent.

IDOR-1117-2520 is a selective and insurmountable antagonist of CCR6 with IC50 of 20 nM.

Compound 32 (HER2) is a potent and selective covalent inhibitor of HER2/WT and HER2/YVMA with IC50 of 49 nM and 42 nM, respectively.

IDE397 is a potent inhibitor of MAT2A, which is developed to selectively exploit this synthetic lethal vulnerability in MTAP−/− tumors.

AK59-51TB (AK59) is a STING degrader leveraging HERC4, a HECT-domain E3 ligase.

UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2.

NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.

NecroX-2 is a small molecule necrosis modulator and potent antioxidant molecule, which can be bound to some types of radicals and especially NAPQI.

PRMT5 inhibitors; PRMT5 inhibitors;

PDE4B-IN-2 is an orally active and selective PDE4B inhibitor with an IC50 of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC50=1.7 µM). PDE4B-IN-2 exhibits potent anti-inflammatory effects.

IM-54 is a cell permeable, potent and selective inhibitor of necrosis.